SCHEMBL3492328

SCHEMBL3492328

COc1ccc(CCl)cc1F

nearest known ligand 0.54

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.54
ALDH1A1 P00352 2/20 0.54
KDM4E B2RXH2 1/20 0.54
MITF O75030 1/20 0.54
TTR P02766 2/20 0.53
CYP17A1 P05093 1/20 0.49
TUBB1 Q9H4B7 1/20 0.49
DBH P09172 1/20 0.48
RAB9A P51151 2/20 0.47
NPC1 O15118 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
LMNA P02545 2/20 0.46
MAPK1 P28482 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methylene Chloride SCHEMBL27528853 0.98 HTT (0.52) HTTALDH1A1KDM4EMITFTTR
SCHEMBL1279242 0.84 TTR (0.54) ALDH1A1KDM4ETTRSMN1; SMN2LMNA
SCHEMBL2759522 0.82 HTT (0.51) HTTALDH1A1KDM4EMITFCYP17A1
SCHEMBL185845 0.81 CA2 (0.68) ALDH1A1KDM4ETTR
SCHEMBL30074670 0.81 CA2 (0.68) ALDH1A1KDM4ETTR
SCHEMBL12509023 0.81 HTT (0.54) HTTALDH1A1KDM4EMITFCYP17A1
Ammonia Solution, Strong SCHEMBL23291273 0.80 HTT (0.50) HTTALDH1A1KDM4EMITFCYP17A1
SCHEMBL2382627 0.80 HTT (0.50) HTTALDH1A1KDM4EMITFCYP17A1
SCHEMBL186570 0.80 HTT (0.50) HTTALDH1A1KDM4EMITFCYP17A1
SCHEMBL7666743 0.80 HTT (0.55) HTTALDH1A1KDM4EMITFCYP17A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109674-A1 ALLOSTERIC MODULATION OF MUSCARINIC ACETYLCHOLINE RECEPTOR EFFICACY THE UNIVERSITY OF TOLEDO (US) 2026-04-23 US disclosed
US-12606557-B2 Substituted indoles with inhibitory activity UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2026-04-21 US disclosed
EP-4548937-A1 ANTIBODY-DRUG COMPLEX Eisai R&D Management Co., Ltd. (JP) 2025-05-07 EP disclosed
US-20250099494-A1 PHOSPHONIC ACID COMPOUND AND PRODRUG THEREOF, AND PREPARATION METHODS FOR AND USES OF PHOSPHONIC ACID COMPOUND AND PRODRUG THEREOF HAIHE BIOPHARMA CO., LTD. (CN) 2025-03-27 US disclosed
EP-4467552-A1 PHOSPHONIC ACID COMPOUND AND PRODRUG THEREOF, AND PREPARATION METHODS FOR AND USES OF PHOSPHONIC ACID COMPOUND AND PRODRUG THEREOF Haihe Biopharma Co., Ltd. (CN) 2024-11-27 EP disclosed
CN-118339172-A Phosphonic acid compounds and prodrugs thereof, preparation method and application thereof 上海海和药物研究开发股份有限公司 2024-07-12 CN disclosed
WO-2024102245-A1 ALLOSTERIC MODULATION OF MUSCARINIC ACETYLCHOLINE RECEPTOR EFFICACY THE UNIVERSITY OF TOLEDO (US) 2024-05-16 WO disclosed
US-20240148895-A1 ANTIBODY-DRUG CONJUGATE EISAI R&D MANAGEMENT CO., LTD. (JP) 2024-05-09 US disclosed
EP-4346805-A1 PYRIMIDINE AND PYRIDINE AMINE COMPOUNDS AND USAGE THEREOF IN DISEASE TREATMENT Epigen Biosciences, Inc. (US) 2024-04-10 EP disclosed
WO-2024043319-A1 ANTIBODY-DRUG COMPLEX エーザイ・アール・アンド・ディー・マネジメント株式会社 2024-02-29 WO disclosed
WO-2002034754-A2 BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE SMITHKLINE BEECHAM P.L.C. (GB) 2002-05-02 WO disclosed
EP-0950056-A2 N-(PYRIDINYLAMINO)ISOINDOLINES AND RELATED COMPOUNDS HOECHST MARION ROUSSEL, INC. (US) 1999-10-20 EP disclosed
WO-1998029407-A2 N-(PYRIDINYLAMINO)ISOINDOLINES FOR TREATING ALZHEIMER'S AND DEPRESSION HOECHST MARION ROUSSEL, INC. (US) 1998-07-09 WO disclosed
CN-1099030-A Biocidal compounds SHELL INT RESEARCH (NL) 1995-02-22 CN disclosed
EP-0623601-A1 N-(3-Fluorobenzyl)heterocyclic derivatives and their use as pesticides SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1994-11-09 EP disclosed
US-5021414-A Antiestrogen IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1991-06-04 US disclosed
US-4904661-A ANTIESTROGENS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1990-02-27 US disclosed
US-4732912-A ANTIESTROGENS, ANTITUMOR AGENTS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1988-03-22 US disclosed
EP-0124369-B1 PHENOL DERIVATIVES IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1987-06-24 EP disclosed
EP-0124369-A1 Phenol derivatives IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1984-11-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260109674-A1 ALLOSTERIC MODULATION OF MUSCARINIC ACETYLCHOLINE RECEPTOR EFFICACY CHRM5, CHRM3, CHRNA3 HTT 1364/4885ALDH1A1 2558/4885KDM4E 2710/4885
US-20240148895-A1 ANTIBODY-DRUG CONJUGATE ANTXR2, FCGR1A, HAX1 HTT 3152/4885ALDH1A1 927/4885KDM4E 2664/4885
US-12606557-B2 Substituted indoles with inhibitory activity IDO1, BCL9, IDO2 HTT 2504/4885ALDH1A1 754/4885KDM4E 1848/4885
US-20250099494-A1 PHOSPHONIC ACID COMPOUND AND PRODRUG THEREOF, AND PREPARATION METHODS FOR AND USES OF PHOSPHONIC ACID COMPOUND AND PRODRUG THEREOF ENPP1, ENPP3, PPA1 HTT 3696/4885ALDH1A1 1602/4885KDM4E 3766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.